Unsupported Price Increase Assessment
ICER will evaluate selected high-impact drugs with substantial price increases that occurred in the last quarter of 2018. ICER will review changes in the evidence base for each of these drugs and assess whether or not new clinical data exists that could suggest that the drugs could be significantly more beneficial for patients than what was previously understood. ICER will publish the final draft of its first UPI report in October 2019.
For questions, please contact Laura Cianciolo, Program Manager, at firstname.lastname@example.org.